THEME : PRESCRIPTION DRUGS



PE n° 2047
2017/08

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.
Vella Bonanno P., Ermisch M., Godman B., Martin A.P., Van Den Bergh J., Bezmelnitsyna L., Bucsics A., Arickx F., Bybau A., Bochenek T., van de Casteele M., Diogene E., Eriksson I., Fürst J., Gad M., Greičiūtė-Kuprijanov I., van der Graaff M., Gulbinovic J., Jones J., Joppi R., Kalaba M., Laius O., Langner I., Mardare I., Markovic-Pekovic V., Magnusson E., Melien O., Meshkov D.O., Petrova G.I., Selke G., Sermet C., Simoens S., Schuurman A., Ramos R., Rodrigues J., Zara C., Zebedin-Brandl E., Haycox A. Front Pharmacol. Frontiers in pharmacology, vol 8, n° 497, 2017/08, 1-13.
 Frontiers in Pharmacology 


2043*

Frailty, polypharmacy, and potentially inappropriate medications in old people: findings in a representative sample of the French population.
Herr M., Sirven N., Grondin H., Pichetti S., Sermet C., European Journal of Clinical Pharmacology, In line: 11/06/2017, 1 -8.
On link.springer.com site

Disinvestment Strategies for Pharmaceuticals: An International Review
Parkinson B., Sermet C., Clement F., Crausaz S., Godman B., Garner S., Choudhury M., Pearson S.A., Viney R., Lopert R., Elshaug A.G.
Issues in Health Economics (Questions d'économie de la santé) n° 220. 2016/08.

2014*

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. Ermisch M., Bucsics A., Vella Bonanno P., Arickx F., Bybau A., Bochenek T., van de Casteele M., Diogene E., Fürst J., Garuoliene K., van der Graaff M., Gulbinovic J., Haycox A., Jones J., Joppi R., Laius O., Langner I., Martin A. P., Markovic-Pekovic V., McCullagh L., Magnusson E., Nilsen E., Selke G., Sermet C., Simoens S., Sauermann R., Schuurman A., Ramos R., Vlahovic-Palcevski V., Zara C., Godman B., Frontiers in Pharmacology, vol 7, article 305, 2016/09, 1-9.
On frontiers in Pharmacology site

2001*

Geographical Disparities in Prescription Practices of Lithium and Clozapine: a Community-based Study.
Verdoux H., Pambrun E., Cortaredona S., Coldefy M., Le Neindre C., Tournier M., Verger P., Acta Psychiatrica Scandinavica, vol 133, 6, June 2016, 470-480.
On onlinelibrary site

Measuring Polypharmacy in the Elderly: Impact of the Method on Prevalence and Therapeutic Classes
Le Cossec C. (Irdes), Sermet C. (Irdes), in collaboration with Perronnin M. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n° 213. 2015/10.

1991*

Generic Pregabalin; Current Situation and Implications for Health Authorities, Generics and Biosimilars Manufacturers in the Future.
Godman B., Wilcock M., Martin A., Bryson S., Baumgärtel C., Bochenek T., de Bruyn W., Sović Brkičić L., D'Agata M., Fogele A., Coma Fusté A., Fraeyman J., Fürst J., Garuoliene K., Herholz H., Hoffmann M., Jayathissa S., Kwon H.-Y., Langner I., Kalaba M., Andersén Karlsson E., Laius O., Markovic-Pekovic V., Magnusson E., McTaggart S., Metcalfe S., Bak Pedersen H., Piessnegger J., Ringerud A.-M., .W Selke G., Sermet C., Schiffers K., Skiold P., Slabý J., Tomek D., Viksna A., Vitry A., Zara C., Malmström R.-E., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 4, n°3, 2015/09, 125-135.
On gabi-journal site

1980*

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.
Parkinson B., Sermet C., Clement F., Crausaz S., Godman B., Garner S., Choudhury M., Pearson S.A., Viney R., Lopert R., Elshaug A.G. Pharmacoeconomics. 1-20 vol 33, Issue 9, 2015/09, 905-924.
(Catégorie 2 - CNRS) - (Cat. A - Hcérès)
On springer link site

1974*

Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Godman B., Malmström R.E., Diogene E., Gray A., Jayathissa S., Timoney A., Acurcio F., Alkan A., Brzezinska A., Bucsics A., Campbell S.M., Czeczot J., de Bruyn W., Eriksson I., Yusof F.A., Finlayson A.E., Fürst J., Garuoliene K., Guerra Júnior A., Gulbinovič J., Jan S., Joppi R., Kalaba M., Magnisson E., McCullagh L., Miikkulainen K., Ofierska-Sujkowska G., Pedersen H.B., Selke G., Sermet C., Spillane S., Supian A., Truter I., Vlahović-Palčevski V., Vien L.E., Vural E.H., Wale J., Władysiuk M., Zeng W., Gustafsson L.L. Expert Review of Clinical Pharmacology, vol 8, n°1, 2015/01, 77-94.

Polypharmacy: definitions, measurement and stakes involved Review of the literature and measurement tests
Monégat M. (Irdes), Sermet C. (Irdes) In collaboration with Perronnin M. (Irdes) and Rococo E. (Institut Gustave Roussy-IGR)
Issues in Health Economics (Questions d'économie de la santé) n° 204. 2014/12.

1963bis*

Entry time effects and follow-on drug competition.
Andrade L.F., Sermet C., Pichetti S., European Journal of Health Economics, on line le 12/12/2014. vol 17 n°1, 2016/01, 45-60.
On springer link site

Index of the first 200 issues of Questions d'économie de la santé
January 1998 – July-August 2014

Issues in Health Economics (Questions d'économie de la santé) hors série. 2014/09.

1919bis*

Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Godman B., Malmström R.E., Diogene E., Jayathissa S., McTaggart S., Cars T., Alvarez-Madrazo S., Baumgärtel C., Brzezinska A., Bucsics A., Campbell S., Eriksson I., Finlayson A., Fürst J., Garuoliene K., Gutiérrez-Ibarluzea I., Hviding K., Herholz H., Joppi R., Kalaba M., Laius O., Malinowska K., Pedersen H.B., Markovic-Pekovic V., Piessnegger J., Selke G., Sermet C., Spillane S., Tomek D., Vončina L., Vlahović-Palčevski V., Wale J., Wladysiuk M., van Woerkom M., Zara C., Gustafsson L.L. Frontiers in Pharmacology. vol 5, article 109, 2014/06, 1-11.
On ncbi site

1818bis*

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
Godman B., Wettermark B., van Woerkom M., Fraeyman J., Alvarez-Madrazo S., Berg C., Bishop I., Bucsics A., Campbell S., Finlayson A.E., Fürst J., Garuoliene K., Herholz H., Kalaba M., Laius O., Piessnegger J., Sermet C., Schwabe U., Vlahović-Palčevski V.V., Markovic-Pekovic V., Vončina L., Malinowska K., Zara C., Gustafsson L.L. Frontiers in Pharmacology, vol 5, article 106, 2014/06, 1-9.
On ncbi site

1928*

Personalizing health care: feasibility and future implications.
Godman B., E. Finlayson A., K. Cheema P., Zebedin-Brandl E., Gutiérrez-Ibarluzea I., Jones J., E. Malmström R., Asola E., Baumgärtel C., Bennie M., Bishop I., Bucsics A., Campbell S., Diogene E., Ferrario A., Fürst J., Garuoliene K., Gomes M., Harris K., Haycox A., Herholz H., Hviding K., Jan S., Kalaba M., Kvalheim C., Laius O., Lööv S.A., Malinowska K., Martin A., McCullagh L., Nilsson F., Paterson K., Schwabe U., Selke G., Sermet C. et al. BMC Medicine, vol 11, 2013/08, 1-23.
On BMC Medicine site

1919*

Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.
Malmström R.E., Godman B.B., Diogene E., Baumgärtel C., Bennie M., Bishop I., Brzezinska A., Bucsics A., Campbell S., Ferrario A., Finlayson A.E., Fürst J., Garuoliene K., Gomes M., Gutiérrez-Ibarluzea I., Haycox A., Hviding K., Herholz H., Hoffmann M., Jan S., Jones J., Joppi R., Kalaba M., Kvalheim C., Laius O., Langner I., Lonsdale J., Lööv S.Å., Malinowska K., McCullagh L., Paterson K., Markovic-Pekovic V., Martin A., Piessnegger J., Selke G., Sermet C., Simoens S., Tulunay C., Tomek D., Vončina L., Vlahovic-Palcevski V., Wale J., Wilcock M., Wladysiuk M., van Woerkom M., Zara C., Gustafsson L.L., Frontiers in pharmacology, vol 4, article 39, 2013/05, 1-31.
On Frontiers site

1917*

Multilevel Analysis of the Influence of Patients' and General Practitioners' Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France.
Pichetti S., Sermet C., Godman B., Campbell S.M., Gustafsson L.L., Applied Health Economics and Health Policy, on line, 2013/04, 1-14.
On Springer Link site

Deductibles and the Demand for Prescription Drugs: Evidence from French Data
Kambia-Chopin B. (Ministère de la Santé et des services sociaux du Québec ; Irdes), Perronnin M. (Irdes ; LEDa-LEGOS, Université Paris I)
Working paper n° 54. 2013/02

How to Explain Price Gaps between Me-too Drugs?
A 2001-2009 Panel-data Analysis

Bergua L. (CHU de Rouen), Cartier T. (Université Paris Diderot, Sorbonne Paris Cité, Irdes), Célant N. (Irdes), Pichetti S. (Irdes), Sermet C. (Irdes), Sorasith C. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n° 178. 2012/07-08.

Entry Time Effects and Follow-on Drugs Competition
Andrade L.F. (Gate-Groupe d'analyse théorique et économique, Lyon ; Irdes)
Working paper n° 49. 2012/06

1906*

Essential to increase the use of generics in Europe to maintain comprehensive health care ?
Godman B., Bennie M., Baumgärtel C., Sovic-Brkicic L., Burkhardt T., Fürst J., Garuoliene K., Gomes M., Markovic-Pekovic V., Martin A., Sermet C., Skiold P., Van Woerkom M., Voncina L., Gustafsson L.L., Farmeconomia. Health economics and therapeutic pathways, 2012, vol 13, Suppl n°3S, 5-20.
On Farmeconomia site

1868*

European payer initiatives to reduce prescribing costs through use of generics.
Godman B., Wettermark B., Sermet C. et al., GaBi Journal : Generics and Biosimilars Initiative Journal, vol. 1, issue 1, 2012, 22-27.
On GaBi Journal site

1868bis*

What lessons can be learned from the launch of generic clopidogrel?
Baumgärtel C., Godman B., Malmstrom R.E., Andersen M., Abuelkhair M., Abdu S., Bennie M., Bishop I., Burkhardt T., Fahmy S., Furst J., Garuoliene K., Herholz H., Kalaba M., Koskinen H., Laius O., Lonsdale J., Malinowska K., Ringerud A.M., Schwabe U., Sermet C., Skiold P., Teixeira I., van Woerkom M., Vitry A., Vončina L., Zara C., Gustafsson L.L., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 1, n°2, 2012, 58-68.
On GaBi Journal site

1868ter*

Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach.
Godman B., Abuelkhair M., Vitry A., Abdu S., Bennie M., Bishop I., Fahmy S., Garuoliene K., Herholz H., Martin A., Malmstrom R.E., Jan S., Schwabe U., Sermet C., Skiold P., Voncina L., Gustaffson L.L., Generics and Biosimilars Initiative Journal (GaBI Journal). vol 1, n°2, 2012, 69-83.
On GaBi Journal site

Analysis of the Impact of Drug Delisting in France between 2002 and 2011
Pichetti S., Sermet C.
Issues in Health Economics (Questions d'économie de la santé) n° 167. 2011/07-08.

1845*

Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on presciption rates: A time-series analysis for France 1998-2010.
Pichetti S., Sorasith C., Sermet C., Health Policy, vol.102, issues 2-3, 2011/10, 159-169.
(Catégorie 2 - CNRS) - (Cat. A - Hcérès)

1818*

Policies to enhance prescribing efficiency in Europe: findings and future implications.
Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., Garuoliene K., Herholz H., Joppi R., Kalaba M., Laius O., Lonsdale J., Malmström R.E., Martikainen J.E., Samaluk V., Sermet C., Schwabe U., Teixeira I., Tilson L., Tulunay F.C., Vlahovic-Palcevski V., Wendykowska K., Wettermark B., Zara C., Gustafsson L.L., Frontiers in pharmacology, vol 1, article 141, 2011/01, 1-16.
On Frontiers site

1815*

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization : changes seen and global implications.
Godman B., Shrank W., Andersen M., Berg C., Bishop I., Burkhardt T., Garuoliene K., Herholz H., Joppi R., Kalaba M., Laius O., McGinn D., Samaluk V., Sermet C., Schwabe U., Teixeira I., Tilson L., Tulunay F.C., Vlahović-Palčevski V., Wendykowska K., Wettermark B., Zara C., Gustafsson L.L., Expert Review of Pharmacoeconomics & Outcomes Research, vol 10, n°6, 2010/12, 707-722.
On Expert reviews site

1813*

Effect of a French experiment of team work between general practitioners and nurses on efficacy and cost of type 2 diabetes patients care.
Mousquès J., Bourgueil Y., Le Fur P., Yilmaz E., Health Policy, vol 98, n°2-3, 2010/12, 131-143.
On Health Policy site

1805

Use of Generics - A Critical Cost Containment Measure for All Healthcare Professionals in Europe ?
Godman B., Shrank W., Wettermark B., Andersen M., Bishop I., Burkhardt T., Garuolienè K., Kalaba M., Laius O., Joppi R., Sermet C., Schwabe U., Teixeira I., Cankat Tulunay F., Wendykowska K., Zara C., L. Gustafsson L., Pharmaceuticals, vol 3, n°2, 2010, 2470-2494.
On MDPI site

1798

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
Adamski J., Godman B., Ofierska-Sujkowska G., Osinska B., Herholzl H., Wendykowska K., Laius O., Jan S., Sermet C., Zara C., Kalaba M., Gustafsson R., Garuoliene K., Haycox A., Garattini S., Gustafsson L.L., BMC Health Services Research, vol 10, n°153, 1-29, 2010/06.
On Biomedcentral site

1780

Ongoing pharmaceutical reforms in France : Implications for Key Stakeholder Groups, Sermet C., Andrieu V., Godman B., Van Ganse E., Haycox A., Reynier J.P., Applied Health Economics and Health Policy, vol 8, n°1, 2010, 7-24
Abstract

Has the Introduction of Mandatory Deductibles Modified Patients' Prescription Drug Purchasing Behaviour?
Kambia-Chopin B., Perronnin M.
Issues in Health Economics (Questions d'économie de la santé) n° 158. 2010/10

Group Practice Dynamics Among Private General Practitioners from 1998 to 2009
Baudier F. (ARS), Bourgueil Y. (Irdes), Evrard I. (Irdes), Gautier A. (Inpes), Le Fur P. (Irdes), Mousquès J. (Irdes)
Issues in Health Economics (Questions d'économie de la santé) n° 157. 2010/09

Drug-prescription Management in Patients with Multiple Chronic Conditions
Clerc P., Le Breton J., Mousquès J., Hebbrecht G., de Pouvourville G.
Issues in Health Economics (Questions d'économie de la santé) n° 156. 2010/07-08

Evolution 1998-2002 of the antidepressant consumption in France, Germany and the United Kingdom.
Grandfils N., Sermet C.
Working paper n° 21, 2009/02

A refutation of the practice style hypothesis: the case of antibiotics prescription by French general practitioners for acute rhinopharyngitis.
Mousquès J. (Irdes) Renaud T. (Irdes) Scemama O. (HAS)
Working paper n° 18, 2008/10

Drug price setting and regulation in France.
Grandfils N.
Working paper n° 16, 2008/09

The 2006 Health, Health Care and Insurance Survey, a Panel for Health Policies Analysis, Public Health and Health Economics Research.
Allonier C., Dourgnon P., Rochereau T.
Issues in Health Economics (Questions d'économie de la santé) n° 131. 2008/04

Delisting of Mucolytics and Expectorants: What is the Impact on General Practitioners' Prescribing?
Devaux M., Grandfils N., Sermet C.
Issues in Health Economics (Questions d'économie de la santé) n° 128. 2007/12

1654

Pharmaceutical policy in France : a mosaic of reforms.Grandfils N., Sermet C., Eurohealth, 2006, vol.12, n° 3, 15-17.
On LSE site

1616

Pharmaceutical regulation in France 1980-2003.Paris V., The International Journal of Health Planning and Management, 2005/11, 307-328.
On Interscience site

The politics of drug reimbursement in England, France and Germany.
N'Guyen L., Or Z., Paris V. , Sermet C.
Issues in Health Economics (Questions d'économie de la santé) n° 99. 2005/10

1542

No significant decrease in antibiotic use from 1992 to 2000, in the French community. Sommet A., Sermet C., Boėlle P.-Y., Tafflet M., Bernède C., Guillemot D., In "Journal of Antimicrobial Chemotherapy" Vol 54, Edité par Oxford University Press, 2004, pp. 1-5.
On Oxford Journals site

1530

Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy). Bouée S., Charlemagne A., Fagnani F., Le Jeunne P., Sermet C., Naudin F., Lancry P.-J., In « Revue du Rhumatisme », vol. 71, n° 5, 2004/05, pp. 378-385.
On ncbi site